Literature DB >> 28762064

Nomogram with potential clinical use to predict lymph node metastasis in endometrial cancer patients diagnosed incidentally by postoperative pathological assessment.

Salih Taşkın1, Yavuz Emre Şükür2, Bulut Varlı1, Kazibe Koyuncu1, Mehmet Murat Seval1, Can Ateş3, Selcen Yüksel4, Mete Güngör5, Fırat Ortaç1.   

Abstract

PURPOSE: To determine the clinical and pathological risk factors for lymph node metastasis (LNM) in patients with endometrial cancer and to create a nomogram to predict LNM in patients without surgical staging.
METHODS: All patients with endometrial adenocarcinoma who were treated surgically at a university based gynecologic oncology clinic between January 2011 and December 2014 were recruited. Women with endometrial adenocarcinoma who were surgically staged including lymphadenectomy were included in the study. Data regarding clinical and pathological risk factors were recorded. The histopathologic slides from the staging surgeries were re-evaluated microscopically by a gynecologic pathologist for all parameters along with lymphovascular space invasion (LVSI).
RESULTS: A total of 279 patients with endometrial cancer were analyzed. Among those, 31 (11.1%) had lymph node metastasis. According to the univariate analyses, elevated CA 125 (>35 U/mL), LVSI, myometrial invasion ≥50%, grade 3 disease, non-endometrioid type, and cervical stromal involvement were significantly associated with LNM. The multivariate logistic regression analysis showed that LVSI, non-endometrioid type, elevated CA 125, and cervical stromal involvement increased the risk of LNM. However, myometrial invasion and grade did not significantly affect the risk of LNM. A nomogram to predict LNM was constructed using these factors (concordance index 0.92).
CONCLUSIONS: LVSI is the most important predictor for LNM. The present nomogram can be useful to decide if adjuvant therapy is required for patients who undergo simple hysterectomy for a benign etiology and incidentally diagnosed with endometrial cancer by pathological evaluation.

Entities:  

Keywords:  Adjuvant therapy; Endometrial cancer; Lymph node metastasis; Lymphovascular space invasion; Nomogram

Mesh:

Substances:

Year:  2017        PMID: 28762064     DOI: 10.1007/s00404-017-4477-7

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  5 in total

1.  Diagnostic Accuracy of Clinical Biomarkers for Preoperative Prediction of Lymph Node Metastasis in Endometrial Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Casper Reijnen; Joanna IntHout; Leon F A G Massuger; Fleur Strobbe; Heidi V N Küsters-Vandevelde; Ingfrid S Haldorsen; Marc P L M Snijders; Johanna M A Pijnenborg
Journal:  Oncologist       Date:  2019-06-11

2.  L1 Cell Adhesion Molecule (L1CAM) expression in endometrioid endometrial carcinomas: A possible pre-operative surrogate of lymph vascular space invasion.

Authors:  Daniela de Freitas; Fernando Nalesso Aguiar; Cristina Anton; Carlos Eduardo Bacchi; Jesus Paula Carvalho; Filomena Marino Carvalho
Journal:  PLoS One       Date:  2018-12-17       Impact factor: 3.240

3.  Prognostic significance of lymphovascular space invasion in patients with endometrioid endometrial cancer: a retrospective study from a single center.

Authors:  Yibo Dai; Yangyang Dong; Yuan Cheng; Hongyi Hou; Jingyuan Wang; Zhiqi Wang; Jianliu Wang
Journal:  J Gynecol Oncol       Date:  2019-11-28       Impact factor: 4.401

4.  Association of Myometrial Invasion With Lymphovascular Space Invasion, Lymph Node Metastasis, Recurrence, and Overall Survival in Endometrial Cancer: A Meta-Analysis of 79 Studies With 68,870 Patients.

Authors:  Jianzhang Wang; Ping Xu; Xueying Yang; Qin Yu; Xinxin Xu; Gen Zou; Xinmei Zhang
Journal:  Front Oncol       Date:  2021-10-21       Impact factor: 6.244

5.  An Externally Validated Nomogram for Predicting Lymph Node Metastasis of Presumed Stage I and II Endometrial Cancer.

Authors:  Yangyang Dong; Yuan Cheng; Wenjuan Tian; Hua Zhang; Zhiqi Wang; Xiaoping Li; Boer Shan; Yulan Ren; Lihui Wei; Huaying Wang; Jianliu Wang
Journal:  Front Oncol       Date:  2019-11-14       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.